[ad_1]
The government provides temporary direct supply until the establishment of a supply system between hospitals and manufacturers.
The new antibody treatment drug for coronavirus infection (Corona 19) developed in Korea, ‘Lecyrona’, will be supplied to medical institutions from the middle of the month.
The Central Defense Response Headquarters (Bang Dae-bon) announced on the 6th that the government will directly purchase Rekkironaju (ingredient name Legdanvimab CT-P59) for a limited time and supply it to medical institutions from mid-February. .
The Ministry of Food and Drug Safety (Ministry of Food and Drug Safety) officially authorized Rekirona, developed by Celltrion the day before, as an antibody treatment for Corona 19.
Daebon Bang explained that it takes time to prepare the product and the treatment is directly supplied by the government for a temporary period, and establishing a supply system between the medical institution and the pharmaceutical company will minimize the inconvenience of use.
Rekironaju is administered only to subjects approved by the Ministry of Food and Drug Safety.
The Ministry of Food and Drug Safety designates patients older than 60 years with the approval of Rekyrona, mild patients with one or more chronic diseases of cardiovascular disease, chronic disease of the respiratory system, diabetes and hypertension (underlying diseases) and patients with pneumonia requiring oxygen therapy.
In each medical institution, these patients can use Rekirona within 7 days after the onset of symptoms.
Copyright © Gyeongbuk Ilbo-Goodday Good News Unauthorized reproduction and redistribution prohibited
See other articles of the Alliance
